BACKGROUND: Pharmaceutical companies are increasingly leveraging machine learning techniques to optimize healthcare research, drug development, and medical affairs activities. AI (artificial intelligence) tools such as chatbots, virtual digital assistants, and research tools have been explored to varying degrees of maturity in industries such as consumer goods or software technology. However, there continues to be untapped opportunities within the pharmaceutical industry to employ these technologies for enhanced engagement and education with healthcare professionals (HCPs). Pharmacists, situated at the crossroads of clinical sciences and innovation, have the potential to elevate their role and significance within the pharmaceutical industry by developing and leveraging such technologies. METHODS: To address this, the python-coded tool, Medical Information (MI) Data Uses For AI Semantic Analysis (MUFASA), utilizes state-of-the-art Sentence Transformer library, clustering, and visualization techniques. MUFASA harnesses unsolicited MI data with AI technology, improving efficiency and providing actionable medical affairs intelligence for targeted content delivery to HCPs. RESULTS: MUFASA optimizes medical affairs activities through its distinctive features: semantic search, cluster analysis, and visualization. Its proficiency in understanding inquiries, as demonstrated through 3D vector mapping and clustering tests, enhances the efficiency of MI and Medical Science Liaison (MSL) case handling. It proves invaluable in training new staff, bolstering response uniformity, and mitigating compliance risks. Leveraging the HDBSCAN algorithm, MUFASA's cluster analysis uncovers deep insights and discerns actionable themes from large inquiry data sets. The visualization graphs, generated from semantic searches, support evidence-based decisions by tracking the effectiveness of initiatives and monitoring trend shifts. Collectively, MUFASA enriches strategic decision-making, cultivates actionable insights, and bolsters healthcare professional engagement. CONCLUSION: There are numerous opportunities for innovation within the intersection of healthcare and data science. Pharmaceutical manufacturers, with one of their medical affairs responsibilities being the collection of unsolicited inquiries, particularly from HCPs, stand poised to leverage machine learning capabilities to optimize its processes. The abundance of data generated by the growing effort to use it in meaningful ways presents an opportunity for pharmaceutical companies to harness machine learning techniques.